<\/p>\n
Warf<\/strong> is 1 \/ 2 \/ 5 mg warfarin tablets from a WHO-GMP certified manufacturer — an oral vitamin K antagonist (VKA) anticoagulant. Warfarin was first synthesised from dicoumarol in the 1940s and approved as a human drug in 1954; despite the rise of DOACs it remains first-line for mechanical heart valves, moderate-to-severe mitral stenosis, and antiphospholipid syndrome. Mechanism: blocks vitamin K epoxide reductase (VKORC1), depleting the active forms of clotting factors II, VII, IX, X plus proteins C and S. Onset is delayed 3-5 days because circulating factors must decay. Dose is highly individualised and INR-driven — target INR 2.0-3.0 in most indications, 2.5-3.5 for mechanical mitral or older aortic prostheses. Daily intake of vitamin K (greens) should be consistent rather than avoided. Major bleeding rate ~1-3%\/year on therapeutic warfarin. Reversal: oral or IV vitamin K plus 4-factor prothrombin complex concentrate for major bleeding. Specialist or family-physician supervision is standard.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n Warf is 1 \/ 2 \/ 5 mg warfarin sodium tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Warfarin is the most widely used oral anticoagulant in the world. Despite the introduction of direct oral anticoagulants (DOACs), warfarin remains the first-line choice in mechanical heart valves, rheumatic mitral stenosis, antiphospholipid syndrome, and selected high-risk patients where DOAC evidence is weak.<\/p>\n Warfarin h\u00e6mmer vitamin K-epoxidreduktase (VKORC1) i hepatocytter og blokerer genanvendelsen af vitamin K. Dette reducerer de aktive \u03b3-carboxylerede former af faktor II, VII, IX og X samt de naturlige antikoagulerende proteiner C og S. Den antikoagulerende effekt forsinkes 3-5 dage, da eksisterende cirkulerende faktorer nedbrydes \u2014 bridging med parenteral heparin eller LMWH er n\u00f8dvendigt, n\u00e5r hurtig antikoagulering er p\u00e5kr\u00e6vet.<\/p>\n Warfarindosis er meget individuel og titreres efter det international normaliserede forhold (INR). Typisk vedligeholdelsesdosis er 2-10 mg dagligt, men sp\u00e6nder fra 15 mg.<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Warf?<\/h2>\n
Hvordan Warfarin virker<\/h2>\n
Godkendte anvendelser<\/h2>\n
\n
Dosering og INR-m\u00e5l<\/h2>\n